Blocking the MAPK pathway for Trk inhibitor resistant cancers

A Memorial Sloan Kettering team uncovers new mechanisms of resistance to Trk inhibitors

Targeting the MAPK pathway could be a key to overcoming a new mechanism of tissue-agnostic therapy resistance identified by a Memorial Sloan Kettering Cancer Center team.

FDA has approved two inhibitors of TrkA, TrkB and TrkC for tissue-agnostic treatment of solid tumors with a NTRK

Read the full 452 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers